The benefits of the earlier use of sacubitril/valsartan in de novo heart failure with reduced ejection fraction patients

AIMS: We evaluated the clinical outcomes and trajectory of cardiac reverse remodelling according to the timing of sacubitril/valsartan (Sac/Val) use in patients with heart failure (HF) with reduced ejection fraction (HFrEF). METHODS AND RESULTS: Patients with de novo HFrEF who used Sac/Val between J...

Descripción completa

Detalles Bibliográficos
Autores principales: Oh, Ji‐Hye, Lee, Jae‐Man, Lee, Hee‐Jung, Hwang, Jongmin, Lee, Cheol Hyun, Cho, Yun‐Kyeong, Park, Hyoung‐Seob, Yoon, Hyuck‐Jun, Chung, Jin‐Wook, Kim, Hyungseop, Nam, Chang‐Wook, Han, Seongwook, Hur, Seung‐Ho, Youn, Jong‐Chan, Kim, In‐Cheol
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9288742/
https://www.ncbi.nlm.nih.gov/pubmed/35484930
http://dx.doi.org/10.1002/ehf2.13940

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9288742/
https://www.ncbi.nlm.nih.gov/pubmed/35484930
http://dx.doi.org/10.1002/ehf2.13940

Ejemplares similares